Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 3Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

ponatinib 2pembrolizumab 2napabucasin 2ficlatuzumab 2entinostat 2Gemcitabine 2Bortezomib 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tetulomab tetraxetan lu-177 1siltuximab 1ruxolitinib 1pralsetinib 1pamiparib 1nirogacestat 1interferon gamma-1b 1denileukin diftitox 1bosutinib 1blinatumomab 1Vorinostat 1Trabectedin 1Radiation 1Oncolytic Virotherapy 1Lutetium 1Leucovorin 1Irinotecan 1Interferon-gamma 1Immunotherapy 1Imatinib Mesylate 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms by Histologic Type × CPI-0610 × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡